TF
AMRX icon

Tompkins Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Tompkins Financial’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-800
Closed -$3K – 375
2020
Q1 		$3K Buy
+800
New +$3.39K ﹤0.01% 372

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Tompkins Financial's AMRX Position: Q2 2020 in Review

Tompkins Financial sold out of Amneal Pharmaceuticals (AMRX) in Q2 2020, closing a stake of 800 shares — an estimated $3K sold.

Tompkins Financial first reported a position in AMRX in Q1 2020 and held it in 1 quarter. The position peaked at $3K in Q1 2020. 139 funds tracked by Wall St. Rank hold AMRX as of Q2 2020.

  • Tompkins Financial reported no remaining Amneal Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Tompkins Financial sold 800 Amneal Pharmaceuticals shares in Q2 2020, an estimated $3K.
  • Tompkins Financial first reported a position in Amneal Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Tompkins Financial's Amneal Pharmaceuticals position peaked at $3K in Q1 2020.
  • 139 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2020.

Based on Tompkins Financial's 13F filing for Q2 2020, filed 29 Jul 2020.